CTO

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nasdaq GM:NTEC) today announced that two poster presentationswere presented with its collaborative partner, Novo Nordisk A/S,relating to GlycoPEGylated recombinant Factor VIIa at the XXIstCongress of the International Society on Thrombosis and Haemostasisin Geneva, Switzerland. The data presented demonstrates thatGlycoPE...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced positive Phase II data on its leadcompound, PRT054021, an oral Factor Xa inhibitor, today at the XXICongress of the International Society on Thrombosis and Haemostasis(ISTH) in Geneva, Switzerland. The EXPERT trial showed thatPRT054021 was safe, effective, and well tolerated for theprevention of venous th...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

- BYETTA also Showed Sustained Improvements in Blood GlucoseControl and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. and Eli Lilly and Company today announcedresults from a study that showed BYETTA(R) (exenatide) injectionsustained improvements in blood sugar levels and progressive weightloss through three and a half years of thera...

New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jun 21, 2007 - BioSantePharmaceuticals, Inc. (AMEX:BPA) today provided comment on theWomen's Health Initiative (WHI) Coronary Artery Calcium Studypublished yesterday in The New England Journal of Medicine (NEJM).The study found that younger menopausal women (aged 50-59) whoreceived a standard dose of estrogen therapy had significantly lesscoronary artery...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, NJ – June 4, 2007 – GentaIncorporated (Nasdaq: GNTA) announced the presentation of resultsfrom a Phase 2 clinical trial of its marketed product, Ganite®(gallium nitrate injection), plus rituximab (Rituxan®;Genentech/IDEC) and dexamethasone in patients with relapsed orrefractory non-Hodgkin’s lymphoma (NHL). The data werepresented at the annual mee...

Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VIONPHARMACEUTICALS, INC. announced that it presented updated clinicaldata in a poster session at the 43rd Annual Meeting of The AmericanSociety of Clinical Oncology (ASCO) on its lead anticancer agentCloretazine(R) (VNP40101M) as a single agent in a Phase II trial inpatients with relapsed or refractory small cell lung cancer....

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alvespimycin, its second-generation Hsp90inhibitor, demonstrated promising antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, N.J., June 04, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the presentation of results from aPhase 2 clinical trial of its marketed product, Ganite(R) (galliumnitrate injection), plus rituximab (Rituxan(R); Genentech/IDEC) anddexamethasone in patients with relapsed or refractory non-Hodgkin'slymphoma (NHL). The data were presented at the annual meeting of...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of life for UCpatients t...

Efficacy and Safety Profile of Basilea's Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress

BASEL, Switzerland, May 21, 2007 - Results from phase IIIclinical trials and further human pharmacology studies werepresented at the 16th Congress of the European Academy ofDermatology and Venereology (EADV). These data highlighted theefficacy and safety profile of alitretinoin as a potential oncedaily oral treatment for patients with severe refractory chronichand eczema. Currentl...

AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage

Clinical Poster Presented at Society for Investigative Dermatology FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermaticsrecently announced new comparative clinical data that indicatesthat OCTN-1 skin cells have the ability to recognize, transport andutilize L-ergothioneine (EGT) as a protector against oxidativedamage, and importantly, that (EGT) acts as a more powerful andefficient a...

GenVec Presents Research on New Ad35 Adenovector at ARVO

GAITHERSBURG, Md.--(BUSINESS WIRE)--May 10, 2007 - GenVec, Inc.(Nasdaq:GNVC) today announced pre-clinical research demonstratingthe ability of the Company's new adenovector, Ad35, to induce andsustain protein production in the eye. Lisa L. Wei, Ph.D., GenVec'sDirector of Pre-Clinical Research, presented a poster, AlternateSerotype Adenovector Gives Long-Term Expression in the Eye, at theAss...

Doctors Outraged Over Growth Hormone Controversy

Two anti-aging preventative medicine doctors say they are outragedover recent media coverage about their advocacy of prescribinghuman growth hormone to treat a hormone deficiency often associatedwith aging. DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adultuse of human growth hormone (HGH) was at the center of a recent NewYork Times article about the founders of the American Ac...

Researchers Identify New Genetic Risk Factors for Type 2 Diabetes

Landmark Study Shows At Least 10 Genetic Variants Are AssociatedWith Adult Onset Diabetes BETHESDA, Md., April 26, 2007 – In the mostcomprehensive look at genetic risk factors for type 2 diabetes todate, a U.S.-Finnish team, working in close collaboration with twoother groups, has identified at least four new genetic variantsassociated with increased risk of diabetes and conf...

Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - AeolusPharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation ofdata by researchers at Loma Linda University Medical Center,National Jewish Medical and Research Center and Duke Universityshowing that one of the Company's metalloporphyrin antioxidants,AEOL 10113, demonstrated protection of healthy normal cells in micewith prostate...

Adventrx Announces Positive Data From Multidrug Therapy With CoFactor

Data Presented at American Association for Cancer Research AnnualMeeting SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,today announced positive results from preclinical studies using amultidr...

New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia

Findings indicate early non-responders unlikely to subsequentlyrespond, have substantially more treatment costs, and may benefitfrom earlier change in treatment strategy COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/-- New data presented at the 2007 International Congress onSchizophrenia Research (ICOSR) suggest that antipsychotic drugresponse be assessed earlier than is p...

ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting

SAN DIEGO, March 29, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,announced today that results from preclinical studies of ANX-510(CoFactor(R)) in combination with intravenous 5-fluorouracil (5-FU)an...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...